Emricasan clinical trials
Also written IDN-6556 and PF-03491390.
- studies test it
- 17
- open now
- 0
- in phase 3
- 0
- first study started
- 2003
How each study uses emricasan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2014 (6)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 6 |
| 2016 | 3 |
| 2017 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 1
Conatus Pharmaceuticals Inc. (12) · Meridian Bioscience, Inc. (2) · Histogen (2) · University of Alberta (1)
Studies
Open first, then newest update. How each study uses emricasan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14CompletedMeridian Bioscience, Inc.NCT03439189Written as EmricasanHow we know
- Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17TerminatedMeridian Bioscience, Inc.NCT03462576Written as EmricasanHow we know
- Caspase Inhibition in Islet TransplantationCompletedPhase 1/2University of AlbertaNCT01653899Written as IDN-6556How we know
- Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal HypertensionCompletedPhase 2HistogenNCT02960204Written as EmricasanHow we know
- Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19TerminatedPhase 1HistogenNCT04803227Written as EmricasanHow we know
- A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCVCompletedPhase 2Conatus Pharmaceuticals Inc.NCT02138253Written as IDN-6556How we know
- Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) FibrosisCompletedPhase 2Conatus Pharmaceuticals Inc.NCT02686762Written as Emricasan (5 mg)How we know
- Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH CirrhosisStatus unknownPhase 2Conatus Pharmaceuticals Inc.NCT03205345Written as Emricasan (25 mg)How we know
- A Study of IDN-6556 in Subjects With Liver CirrhosisCompletedPhase 2Conatus Pharmaceuticals Inc.NCT02230670Written as IDN-6556How we know
- A Study of IDN-6556 in Cirrhotic Subjects With Portal HypertensionCompletedPhase 2Conatus Pharmaceuticals Inc.NCT02230683Written as IDN-6556How we know
- Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid TherapyTerminatedPhase 2Conatus Pharmaceuticals Inc.NCT01912404Written as IDN-6556How we know
- A Study of IDN-6556 in Subjects With NAFLD and Raised TransaminasesCompletedPhase 2Conatus Pharmaceuticals Inc.NCT02077374Written as IDN-6556How we know
- Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLFTerminatedPhase 2Conatus Pharmaceuticals Inc.NCT01937130Written as IDN-6556How we know
- PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy VolunteersCompletedPhase 1Conatus Pharmaceuticals Inc.NCT02121860Written as IDN-6556How we know
- PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy VolunteersCompletedPhase 1Conatus Pharmaceuticals Inc.NCT02039817Written as IDN-6556How we know
- A Caspase Inhibitor in Chronic Hepatitis C (HCV) PatientsCompletedPhase 2Conatus Pharmaceuticals Inc.NCT00088140Written as IDN-6556How we know
- Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver TransplantationCompletedPhase 2Conatus Pharmaceuticals Inc.NCT00080236Written as IDN-6556How we know
Codes
What other systems call emricasan · ClinicalTrials.gg INT004657
- UNII (FDA) P0GMS9N47QEMRICASANConfirmed FDA, Wikidata
- Wikidata Q27077178emricasanConfirmed FDA, Wikidata
- NCI Thesaurus C76660EmricasanOne source FDA
- DrugBank DB05408One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | P0GMS9N47Q | EMRICASAN | Confirmed FDA, Wikidata |
| Wikidata | Q27077178 | emricasan | Confirmed FDA, Wikidata |
| NCI Thesaurus | C76660 | Emricasan | One source FDA |
| DrugBank | DB05408 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.